These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 6443766)
1. Biochemical and physiologic basis for susceptibility and resistance of Pseudomonas aeruginosa to antimicrobial agents. Sabath LD Rev Infect Dis; 1984; 6 Suppl 3():S643-56. PubMed ID: 6443766 [TBL] [Abstract][Full Text] [Related]
2. Occurrence of antipseudomonal beta-lactams and aminoglycosides resistance in Pseudomonas aeruginosa during therapy. Pagani L; Scarabelli M; Cereda PM; Debiaggi M Microbiologica; 1987 Jan; 10(1):103-10. PubMed ID: 3106759 [TBL] [Abstract][Full Text] [Related]
3. Emergence of resistance to beta-lactam antibiotics in Pseudomonas aeruginosa during treatment with new beta-lactams. Lerner SA; Quinn JP Chemioterapia; 1985 Feb; 4(1):95-101. PubMed ID: 3921267 [TBL] [Abstract][Full Text] [Related]
4. Pseudomonas aeruginosa: arsenal of resistance mechanisms, decades of changing resistance profiles, and future antimicrobial therapies. El Zowalaty ME; Al Thani AA; Webster TJ; El Zowalaty AE; Schweizer HP; Nasrallah GK; Marei HE; Ashour HM Future Microbiol; 2015; 10(10):1683-706. PubMed ID: 26439366 [TBL] [Abstract][Full Text] [Related]
5. Susceptibility of Pseudomonas aeruginosa strains isolated from hospitalized children. Patzer J; Walkiewicz R; Dzierzanowska D J Antimicrob Chemother; 1986 Jul; 18(1):45-9. PubMed ID: 3093444 [TBL] [Abstract][Full Text] [Related]
6. Emergence of resistance to beta-lactam and aminoglycoside antibiotics during moxalactam therapy of Pseudomonas aeruginosa infections. Preheim LC; Penn RG; Sanders CC; Goering RV; Giger DK Antimicrob Agents Chemother; 1982 Dec; 22(6):1037-41. PubMed ID: 6218778 [TBL] [Abstract][Full Text] [Related]
7. Penicillin-binding protein 3 is a common adaptive target among Pseudomonas aeruginosa isolates from adult cystic fibrosis patients treated with β-lactams. Clark ST; Sinha U; Zhang Y; Wang PW; Donaldson SL; Coburn B; Waters VJ; Yau YCW; Tullis DE; Guttman DS; Hwang DM Int J Antimicrob Agents; 2019 May; 53(5):620-628. PubMed ID: 30664925 [TBL] [Abstract][Full Text] [Related]
8. Aminoglycoside resistance in Pseudomonas aeruginosa. Poole K Antimicrob Agents Chemother; 2005 Feb; 49(2):479-87. PubMed ID: 15673721 [No Abstract] [Full Text] [Related]
9. Analysis of resistance, cross-resistance and antimicrobial combinations for Pseudomonas aeruginosa isolates from 1997 to 2009. Master RN; Clark RB; Karlowsky JA; Ramirez J; Bordon JM Int J Antimicrob Agents; 2011 Oct; 38(4):291-5. PubMed ID: 21737249 [TBL] [Abstract][Full Text] [Related]
12. Roles of porin and beta-lactamase in beta-lactam resistance of Pseudomonas aeruginosa. Hancock RE; Woodruff WA Rev Infect Dis; 1988; 10(4):770-5. PubMed ID: 2460909 [TBL] [Abstract][Full Text] [Related]
13. [Resistance caused by hyperproduction of chromosomal beta-lactamase in Pseudomonas aeruginosa]. Tirado M; Hermida M; Reig R; Esteva C; Vidal R; Roy C Enferm Infecc Microbiol Clin; 1989 Dec; 7(10):530-4. PubMed ID: 2518765 [TBL] [Abstract][Full Text] [Related]
19. Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. Rossolini GM; Mantengoli E Clin Microbiol Infect; 2005 Jul; 11 Suppl 4():17-32. PubMed ID: 15953020 [TBL] [Abstract][Full Text] [Related]
20. Virulence of Pseudomonas aeruginosa strains with mechanisms of microbial persistence for beta-lactam and aminoglycoside antibiotics in a mouse infection model. Bryan LE; Godfrey AJ; Schollardt T Can J Microbiol; 1985 Apr; 31(4):377-80. PubMed ID: 3924387 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]